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Ideally, tumors that might cause morbidity and mortality should be treated, preferably early, with proven, convincing,
and effective therapy to prevent tumor progression or recurrence, while maintaining a favorable risk-benefit profile for
the individual patient. For patients with colorectal cancer (CRC), this diagnostic, prognostic, and therapeutic precision
is currently impossible. Despite significant improvements in diagnostic procedures, a sizable number of patients with
CRC have liver metastases either at presentation or will subsequently develop it. And in many parts of the world, most
cancer-related deaths are still due to metastases that are resistant to conventional therapy. Metastases to the liver occur
in more than 50% of patients with CRC and represent the major determinant of outcome following curative treatment
of the primary tumor. Liver resection offers the best chance of cure for metastases confined to the liver. However, due
to a paucity of randomized controlled trials, its timing is controversial and a hotly debated topic. This article reviews
some of the main controversies surrounding the surgical management of colorectal cancer liver metastases (CRLM).
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Despite significant improvements in diagnostic proce-
dures, surgical techniques, local and systemic treatment
options, and general patient care, most cancer-related
deaths are still due to metastases that are resistant to con-
ventional therapies. Next to lymph nodes, the liver is the
most common site of metastases from human solid tu-
mors [1]. Metastases to the liver occur in more than 50%
of patients with CRC and represent the major determinant
of outcome following curative treatment of the primary
tumor [2]. Indeed, for nearly one-third of patients with
CRC the liver is the only site of metastatic disease [1].
About 14% to 35% of patients with CRC have liver metas-
tases at presentation, and another one-third will subse-
quently develop it [3-8]. Liver resection offers the only
chance of cure for metastases confined to the liver with
5-year overall survival rates up to 58% [9-12]. Unfortu-
nately, the majority of patients with CRLM are not amen-
able to surgery initially, and the reported rate of successfulCorrespondence: woubet.kassahun@uniklinik-leipzig.de
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unless otherwise stated.resection has ranged from 20% to 30% [13,14]. Some of
the reasons for the low rate of successful liver resection
are: disseminated disease with concomitant extrahepatic
metastases, lack of a sufficient future remnant liver, and
unfavorable anatomical location in the liver. These
patients may become surgical candidates following con-
version chemotherapy that downsize metastatic disease
[15]. In appropriately selected patients with primarily in-
operable liver metastases, secondary resection after down-
staging chemotherapy may afford long-term outcomes
comparable to primary resection [15,16]. Overall, however,
despite the advances made in the last decades, outcome
after liver resection for CRLM as a primary or a two-stage
resection is heterogeneous, and many patients still do
poorly even after careful selection and a successful removal
of the metastatic lesion [17]. The main problem is that pa-
tients who actually undergo successful liver resection have
a high risk of developing recurrent disease, either in the
liver or elsewhere. This occurs in approximately 60% to
70% of patients after primary liver resection and roughly
one-third of these patients die within 2 years of surgery for
CRLM [18-20]. Patients with untreated liver metastases
have a median survival of less than 12 months and a 5-yearis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cing evidence, there are areas of controversies related to
treatment protocols of patients with CRLM. Almost all
studies regarding these controversial issues are nonrando-
mized studies with inherent limitations and representative
data from prospective randomized trials is still missing.
In this contribution, I focus on current controversies sur-
rounding the management of CRLM (Table 1).
Review
Simultaneous versus staged resection of colorectal cancer
liver metastases
One of the controversial issues is the optimal timing of
liver resection for resectable synchronous colorectal liver
metastases (SCRLM). Traditionally, colorectal cancer and
SCRLM have been approached with staged initial resection
of the primary tumor followed by liver resection. But the
paradigm for surgical management of SCRLM has begun
to change, with authors reporting good results for simul-
taneous surgical removal of the primary tumor and the
liver metastases [24-26]. In the simultaneous approach, the
liver metastases and the primary tumor are resectedTable 1 Summarized highlights of controversies surrounding
Treatment strategy Arguments in support of
The simultaneous
approach
No increase of morbidity and/or mortality in carefully
selected patients
Removal of all cancer in a single procedure; thereby
lowering the risk of disease dissemination
Similar PFS and OS compared to those with staged r
Pre-HR chemotherapy Decreases the magnitude of resection
Eradicates micrometastases
Increases R0 resection rates
Assesses responsiveness to specific chemotherapy, th
identifying and selecting patients with favorable tum
biology. It improves PFS
Extensive resection
for DLM
Response on imaging does not necessarily signify cli
or pathological response ( in up to 83% evidence of
residual disease); so resect all initial sites if possible,
despite disappearance on imaging
The liver-first
approach
It is the liver metastasis, rather than the primary tum
gives rise to systematic metastatic disease, so it shou
addressed first
It avoids the risk for progression of CRLM while the p
treated for the primary tumor, especially if complicat
encountered; thereby improving median survival and
3-year survival rates
Option to give systemic chemotherapy as a first step e
treatment course that may lead to an effective respon
primary tumor and avoids resection
CRLM, colorectal liver metastasis; DLM, disappearing (no longer visible on imaging)
overall survival; Pre-HR chemotherapy, neoadjuvant chemotherapy for resectable CRat the same time. The main objective of this approach
is cure thorough the removal of all cancer tissue during a
single operation, thus, avoiding delay of surgical treatment
of liver metastases. Some evidence suggests that patients
with SCRLM who are treated with simultaneous resection
of CRC and CRLM have similar long-term outcomes to
those treated with a staged approach; and the simultan-
eous approach does not increase the morbidity or mortal-
ity associated with liver resection [27-33]. The major
limitation of the simultaneous approach is that the mor-
tality and morbidity of major liver resection, combined
with bowel resection, are likely to be considerable; in some
studies as high as 8% and 36% respectively [34-37]. In a
large retrospective review, Reddy et al. [37] found that
simultaneous colorectal and major liver resections in-
creased morbidity and mortality by more than threefold
compared with major liver resection alone and that the in-
creased severe morbidity was maintained when compared
with the added severe morbidity of staged colorectal plus
liver resection. According to these authors, simultaneous
procedures should only be pursued for minor liver re-
sections with application to major liver resection on athe management of colorectal cancer liver metastases
Arguments against
Considerable increase of morbidity and/or mortality
No time-test approach to evaluate the biological behavior
of metastasis and this may result in unnecessary liver
resection in rapidly progressing disease
esection Higher recurrence rate and a negative impact on
long-term outcome
Delays liver resection and may result in a unresectable
state in nonresponders
May lead to liver parenchyma damage and increased
postoperative morbidity
No impact on PFS and OS
us,
or
nical Hence, durable clinical response is as high as 62%, resect
only residual macroscopic disease leaving the disappeared




No, it is the primary tumor that produces systemic effects
promoting angiogenesis in the liver, thus favoring the
spread of metastatic disease
atient is
ions are
Despite apparently similar treatment protocols in those few
studies, the variations in survival rates of the liver-first approach
are wide; so its comparison with the bowel-first approach or
the combined strategy is problematic
arly in the
se in the
liver metastases; HR, hepatic resection; PFS, progression free survival; OS,
LM.
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[38], these authors recommend avoiding the simultaneous
approach in the following situations: 1) when SCRLM is
noted on exploration for emergency situations such as co-
lonic perforation (high risk of occult distant metastatic
disease), bowel obstruction and bleeding; 2) in those pa-
tients with an extremely increased risk of postoperative
liver failure, such as patients with liver cirrhosis or other
long-standing chronic liver disease; and 3) in patients in
whom the future remnant liver will provide inadequate
hepatic function. A meta-analysis of 2,880 patients with
SCRLM who were followed up for at least 36 months re-
ported that simultaneous resection is as safe as delayed re-
section as long as patients were less than 70 years old and
without severe coexisting disease [39]. Similarly, in the
study of Thelen et al. [40], patients with the simultaneous
approach had far higher mortality than staged, which was
associated with age >70 years and major hepatectomy.
Furthermore, a time test approach has been suggested by
some authors favoring the staged strategy to evaluate the
biological behavior of the metastatic disease, to treat po-
tentially occult disease, and to avoid liver resection in pa-
tients with rapidly progressing disease [41]. And lastly,Table 2 Large retrospective studies focusing on comparison o
treatment of colorectal cancer liver metastases
Author Na Year Approach, n Morbidity, % Mortality, %
Capussotti [29] 79 2007 31 simul 33 0
48 staged 56 1,3
Lyass [25] 112 2001 26 simul 27 0
86 staged 35 2.3
Bolton [35] 165 2000 50 simulb nr 17
115 staged nr 1
de Haas [42] 228 2010 55 simul 11 0
173 staged 25 0.6
Martin RC [33] 230 2009 70 simul 56 0
160 staged 55 4
Martin R [26] 240 2003 134 simul 49 2
106 staged 67 2
Reddy [37] 610 2007 135 simul 36 1
475 staged 18 0.5
Nordlinger [34] 1008 1996 115 simul nr 7
893 staged nr 2
aOnly those studies with N ≥50 were considered in this table.
bLiver resection was carried out simultaneously with or within 3 months of colorect
HR, hepatic resection; N, total number of patients; n, number of patients treated wi
colorectal liver metastasis; simul, simultaneous resection of the primary tumor andthere is some evidence that the simultaneous approach
has a negative effect on progression-free survival (PFS)
[37,38,42]. Therefore, given the results of the above-
mentioned studies (all nonrandomized retrospective)
and other results [25,26,34,43] (Table 2), the simultaneous
approach can be offered only in a highly selected subset
of patients pending additional high-quality evidence.
Currently, no randomized controlled trials on the relative
merits of different therapeutic approaches are available;
thus, there is no evidenced surgical practice that became
as standard of care for resectable SCRLM. Thus, in evalu-
ations of the utility of simultaneous resection of CRC and
CRLM, surgeons should carefully consider the additional
morbidity and mortality associated with the procedure, as
well as the possible improvement in survival.
The role of chemotherapy in neoadjuvant setting
In cases of unresectable CRLM, there is no controversy as
the only practical option is systemic chemotherapy. How-
ever, whether preoperative chemotherapy in patients with
resectable CRLM confers a benefit in terms of decreased
recurrence or improved survival is not clear. Thus, the
balance between the risks and benefits of preoperativef the simultaneous versus the staged approach for the
Conclusions
Mortality rates are similar in both procedures, so the simultaneous
procedure can be performed in carefully selected patients
Because of lower mortality rates and similar OS compared to staged,
Simultaneous resection is a safe and efficient procedure for the
treatment of resectable SCRLM
The mortality rate is higher if liver resection is combined with colorectal
resection. Therefore, patients should have hepatic resection delayed for
at least 3 months after colon resection
The simultaneous approach is safe for limited HR
However, the higher recurrence rate observed in studied patients makes
its oncological value and use in clinical practice questionable
Morbidity and mortality rates are comparable in both procedures.
Therefore, Simultaneous resection is an acceptable option in patients
with resectable SCRLM
Simultaneous resection should be considered a safe option in patients with
resectable SCRLM, because it offers reduced morbidity, shorter treatment
time, and similar survival outcomes
Simultaneous resection is safe and should be considered for patients with
SCRLM; however, due to higher morbidity compared to staged resection
only in those patients whose hepatic tumor burden is amenable to minor
liver resection (less than three segments)
The mortality rate is increased when a major liver resection is performed
simultaneously with the resection of the primary tumor
Therefore, this procedure is recommended only if it can be done with a
minor liver resection and through the same abdominal incision
al resection.
th simultaneous or staged resection; nr, not reported; SCRLM, simultaneous
SCRLM.
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debates originated decades ago, yet are still ongoing
despite interim advancements in other domains of oncol-
ogy. The arguments in support of preoperative chemo-
therapy are based on the fact that this treatment modality
decreases the magnitude of resection, eradicates micro-
metastases, increases R0 resection rates, and aids in the
selection of adjuvant therapy based on assessments of re-
sponsiveness to a specific chemotherapy. It also identifies
patients with aggressive tumor biology in whom liver re-
section may not be appropriate. In their retrospective
study of 131 patients who underwent liver resection for
CRLM, Adam et al. [45] found that patients whose meta-
static lesions progressed during chemotherapy had a sig-
nificantly poorer long-term prognosis (8% versus 37%
5-year survival). However, it can be equally argued that
neoadjuvant chemotherapy (NC) delays liver resection and
may increase the risk of tumor progression to an unresect-
able state if the patient does not respond to chemotherapy
[8,46-49]. Moreover, in their series of 1,471 patients with
resectable metachronous CRLM, Adam et al. [50] com-
pared those who received NC with those treated by liver
resection alone. The authors found that postoperative
complications were significantly higher in the chemo-
therapy group, and more importantly, NC did not im-
prove overall survival (OS). Thus, although NC may
provide earlier control of disseminated disease, it induces
histologic changes in the liver including steatohepatitis
and vascular injury that may result in increased postopera-
tive complications [50-55]. Others disagree with this view
[56,57]. In a randomized controlled trial of 364 patients
(European Organization for Research and Treatment of
Cancer: EORTC 40983) with resectable CRLM, Nordlinger
et al. [57] compared patients who received 12 cycles of
FOLFOX (6 cycles before surgery and 6 cycles after) with
patients treated by liver resection alone. Their result
have not shown these harmful effects and showed a
progression-free survival (PFS) of 36.2% at 3 years in the
chemotherapy group compared to 28.1% (P = 0.041) in the
surgery-alone group. However, at a median follow-up of
8.5 years, no significant improvement in OS had been ob-
served in the chemotherapy group compared to surgery
alone [58]. Moreover, this study failed to prove whether the
indicated benefit of PFS in the chemotherapy group related
to neoadjuvant treatment, adjuvant treatment or a combin-
ation of both. In the series of Nanji et al. [59], a total of 284
out of 293 patients with resectable CRLM underwent liver
resection without NC. These authors reported a 3-year PFS
and a 5-year OS of 46.2% and 55%, respectively. These
conflicting data have led many experts to dispute the ne-
cessity of administering preoperative chemotherapy for
primarily resectable liver metastases altogether.
Given the benefit of PFS seen in the EORTC 40983,
Nordlinger et al. [57,58] advocated the use of preoperativechemotherapy as the standard of care for patients with op-
erable liver metastases. Conversely, others suggest surgery
without preoperative chemotherapy for this population of
patients, basing their argument on chemotherapy-induced
liver injury with increased morbidity, the potential loss of
that particular regimen of chemotherapy from future lines
of treatment, and the nonbeneficial effect of chemother-
apy on long-term survival [59-61] (Table 3).
In summary, the final decision on the timing of liver re-
section (upfront or after NC) should depend on the pref-
erence of the patient and of the interdisciplinary tumor
board that includes the surgeon, the radiologist, the on-
cologist, the radiation therapist, and others working to-
gether. It should be made for the individual patient on the
basis of the best available medical evidence in the context
of the clinical situation.
Regarding adjuvant chemotherapy (AC) after liver re-
section, there are several studies that have demonstrated
its benefit [19,62-66]. These positive results were taken
by many as an answer to the benefit of AC after liver re-
section, and its use has become routine. However, the
majority of these studies are retrospective. No random-
ized controlled trials have examined the benefit of AC
after curative liver resection; any such trial would re-
quire a large sample size and prolonged follow-up. Two
prospective randomized trials that intended to show the
benefit of AC had to close prematurely because of slow
accrual, thus lacking the statistical power to demonstrate
the predefined difference in survival [67,68]. Therefore,
the benefit of AC after liver resection for CRLM has not
been rigorously validated in clinical trials.
Disappearing (no longer visible on imaging) liver
metastases
Given recent therapeutic advances, the nihilism that de-
cades ago often characterized the treatment of patients
with CRLM has been replaced by a measure of excitement.
Along with advances in operative technique and imaging
that have clearly contributed to improvements in the man-
agement of patients with CRLM, recent therapeutic ad-
vances have been stimulated in part through identification
of cellular processes characteristic of CRC that permit
therapeutic targeting with favorable therapeutic index. Fol-
lowing the introduction of new, more effective cytotoxic
agents, tumor response has improved significantly [69-74].
Disappearing liver metastases (DLM) refers to the complete
response or disappearance of a liver metastasis on imaging
after administration of preoperative chemotherapy [75].
Depending on the quality and type of cross-sectional
imaging, DLM occur in up to a quarter of patients who
undergo preoperative systemic chemotherapy either in
neoadjuvant setting for initially resectable liver metastases
or as conversion chemotherapy for initially unresectable
metastases in an attempt to bring patients to potentially
Table 3 Review of large studies (all retrospective except [57,58]) focusing on a comparison of neoadjuvant chemotherapy
followed by hepatic resection versus hepatic resection alone for resectable colorectal cancer liver metastases
Author Year Na TT, n Morbidity, % Mortality, % PFS, mo OS, m Conclusions
Mehta [54] 2008 173 130 NC+HR
43 HR alone
nr nr nr nr NC was associated with regimen-specific hepatic
injury. However, this did not increase postoperative
morbidity and Mortalitynr nr nr nr
Scoggins [55] 2009 186 112 NC+HR 49 0 40 56 Similar remarks as Mehta et. Al
74 HR alone 47 7 56 65
Pawlik [53] 2007 212 153 NC+HR
59 HR alone
35 0 nr nr Preoperative chemotherapy is associated with
hepatic injury in 20 to 30% of patients and the
type of injury was regimen-specific30 4 nr nr
Nordlinger [57,58] 2008 364 151 NC+HR
152 HR alone
25 0.66 19 61 In resectable CRLM, bChemotherapy does not
improve OS. However, it improves PFS
16 1.3 12 54
Vauthey [52] 2006 406 248 NC+HR
158 HR alone
23 14.7 nr nr NC induces regimen-specific significant liver
injury and increases mortality after liver resection
18 1.6 nr nr
Welsh [56] 2007 497 252 NC+HR 29 2 nr nr Liver resection for CRLM is safe following NC
245 HR 27 2 nr nr
Reddy [61] 2009 499 297 NC+HR nr nr nr 53 NC was not associated with improved RFS and OS
202 HR alone nr nr nr 36
cAdam [50] 2010 1471 169 NC+HR 37 2.1 nr nr NC did not improve the outcome of patients
with resectable CRLM
1302 HR alone 24 1.9 nr nr
aOnly those studies with N ≥150 and relatively comparable number of patients in both treatment options were considered in this table.
bChemotherapy was administered as perioperative (before and after hepatic resection); cPFS and OS are reported not in months but in % and there is no
significant difference in both groups.
HR, hepatic resection; N, total number of patients; n, number of patients in either of the treatment options; NC, neoadjuvant chemotherapy for liver metastases;
nr, not reported; TT, type of treatment.
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lesion (less than 2 cm) and prolonged duration of sys-
temic chemotherapy may increase the likelihood of DLM
[78,79]. The management of DLM is challenging because
a complete response on imaging does not necessarily
signify a complete clinical or pathological response. It
can be the result of chemotherapy associated parenchy-
mal changes to the liver such as steatosis and steatohe-
patitis that alter the imaging characteristics of the liver
and lead to a reduction in the sensitivity of imaging during
chemotherapy [80,81]. A durable clinical response for
DLM occurs in about 20% to 50% of patients treated
with systemic chemotherapy alone, leaving a subset of pa-
tients with undiagnosed microscopic liver metastases,
which develop subsequent intrahepatic recurrence [75,79].
Study results regarding the outcome of DLM are dis-
crepant and conflicting. In a report of Elias et al. [82],
27% of the DLMs were identified at laparotomy, whereas
recurrence occurred in 20% of the studied patients. In
the remaining 53%, follow-up showed no recurrence after
31 months. In their second series Elias et al. [77] reported
that 10 (62%) out of 16 patients with DLM remained
recurrence-free at 51 months. In the series of Auer et al.
[78], 17 (44%) out of 39 patients with DLM developed
an intrahepatic recurrence, 8 (21%) patients developed
a recurrence at an extrahepatic site, and 17 (44%)patients remained recurrence-free at a median follow-up
of 40 months. These authors found that the use of hepatic
arterial chemotherapy, disappearance of the metastatic
lesion on MRI and normalization of serum carcinoem-
bryonic antigen (CEA) as independent predictors of a true
response. By contrast, in the study of Benoist et al. [76]
macroscopic residual disease was found in more than 25%
of DLM during laparotomy at the site of liver metasta-
ses that were considered to have disappeared on imaging.
Overall, these authors observed evidence of residual dis-
ease in 83% of DLMs.
To summarize, although the beneficial effect of resec-
tion of hepatic metastases on survival has been clear, the
extent of primary surgery needed in DLM has not. Thus,
controversy persists with regard to the extent of surgery
required for patients with DLM. There are several pro-
posed management strategies for this subset of patients.
These include: resection of all initial sites of DLM when
possible; surgical removal of residual macroscopic disease
while leaving the disappeared lesions in situ if the resec-
tion would be too extensive, leaving insufficient remnant
liver; resection followed by additional adjuvant chemo-
therapy; continuing systemic chemotherapy alone; and
others. No strong evidence from randomized controlled
trials exists to support any of these management options,
particularly the routine use of risky and extensive liver
Kassahun World Journal of Surgical Oncology  (2015) 13:61 Page 6 of 10resection in patients with DLM. For now, clinicians must
use their best judgment taking a risk-benefit approach to
establish the extent of surgical treatment. In the future,
decision aids, such as one tested in a randomized con-
trolled trial, might play a greater part in decision making
about the treatment strategies of DLM.
The liver-first approach
Contrary to the classic bowel-first approach, the liver-
first approach is the reverse of the classic approach and
begins with systemic chemotherapy directed against the
liver metastases, followed by liver resection, then che-
moradiotherapy for patients with rectal cancer, and colo-
rectal resection as the last surgical step. This approach
has been proposed for patients with advanced synchron-
ous CRLM, and in particular for those whom the pri-
mary is located in the rectum and is asymptomatic [83].
In relation to chemotherapy, treatment after liver resec-
tion could be regarded as neoadjuvant for the primary
disease, and adjuvant treatment is given after surgery for
both liver metastases and colorectal cancer. Given the
prognostic decisive role of liver metastases in long-term
survival, the liver-first approach has a theoretical advan-
tage. This new trend has been driven in part by efforts to
improve survival. The option of giving systemic chemo-
therapy early in the treatment course provides a chance to
evaluate a response and thereby define the tumor biology
of the metastatic lesions. In addition the liver-first ap-
proach is the result of the assumption that it is the liver
metastasis, rather than the primary tumor, that gives rise
to systemic metastatic disease. It underlies the importanceFigure 1 Summary of general management strategy for patients with
liver metastases.of prioritizing treatment of the most problematic compo-
nent of the patient’s disease. Thus, considering the time
needed for neoadjuvant chemoradiation and resection of
rectal cancer, which is longer than 3 months [84], address-
ing the liver first may avoid the risk for progression of
CRLM while the patient is being treated for the primary
tumor, which is a concern in the classic approach. This
view has been supported by some studies (all nonrando-
mized) that showed a median survival up to 44 months
and 3-year survival rates as high as 83% [8,46-48]. Data to
support this argument is limited, and there is a counterev-
idence to suggest that it is the primary tumor that pro-
duces systemic effects promoting angiogenesis in the liver
and thus favoring the spread of metastatic disease [85,86].
Moreover, despite apparently similar treatment protocols
used in those few studies, the variations in survival rates
of the liver-first approach are wide [47,48]. This makes its
comparison with other treatment protocols, such as the
bowel-first approach or the combined strategy, difficult.
An adequately powered randomized controlled trial exam-
ining the effect of the liver-first approach on recurrence
and long-term survival might be logistically challenging,
because of the need for a large sample size. Thus, to date,
no randomized, controlled studies have assessed the bene-
fits of this modern strategy or its effects on recurrence
and long-term survival of patients with CRLM.
Unresectable liver metastases and asymptomatic primary
tumor
Historically, the common treatment strategy in patients
with asymptomatic primary tumor with synchronouscolorectal cancer hepatic metastases. CRLM, colorectal cancer
Kassahun World Journal of Surgical Oncology  (2015) 13:61 Page 7 of 10unresectable liver metastases is surgical removal of the
primary tumor followed by systemic chemotherapy. The
theoretical basis that supports this approach is that
the growth of the primary tumor is the main cause of
major complications such as intestinal obstruction, perfor-
ation and hemorrhage, so resection should be more likely
to prevent these complications while achieving best palli-
ation in terms of quality of life [87-89]. Further, resection
of the primary tumor reduces the risk of the growth of
additional metastatic disease that may influence long-
term outcomes. Results of retrospective studies show that
with an estimated survival advantage of 6 months, pri-
marily resected patients live significantly longer than
non-resected patients [90-93]. Moreover, patients put on
initial systemic chemotherapy tended to have more major
complications that mandated surgical intervention and
termination of chemotherapy. Bowel obstruction is the
most frequently encountered complication during chemo-
therapy with a rate ranging from 5.6% to 29% followed by
bleeding from the primary tumor that was experienced by
3% to 5% of the patients [90,93-95].
On the other side, results of comparative studies dem-
onstrate that most patients with widely metastatic disease
will not experience a complication resulting from an non-
resected primary tumor, and that the rate of intestinal ob-
struction due to subsequent growth of the primary tumor
is similar to that caused by adhesions after colorectal
resection [96]. Initial systemic therapy is safe and patients
put on this treatment modality showed an overall re-
sponse rate as high as 70% [18,92,97]. According to one
report, 93% of patients initially treated by systemic chemo-
therapy never required emergency surgery [98]. Overall
morbidity and mortality after resection for advanced meta-
static colorectal cancer were as high as 21% and 16%, re-
spectively [99,100]. This figure is significantly higher than
that of colorectal cancer in general [100,101]. More-
over, experimental data show that resection of the pri-
mary tumor may enhance the growth and proliferation of
metastatic cells [89,102,103]. The underlying mechanism
is thought to be lack of a circulating anti-angiogenic fac-
tor, normally produced by the primary tumor that leads to
suppression of angiogenesis and enhanced apoptosis and
hence inhibiting metastatic progression. All this suggests
that any benefit to preventing the growth of additional
metastases by resection of the primary tumor does not in-
fluence long-term outcome.
In summary, studies examining the effect of primary
surgery on long-term outcomes in patients with asymp-
tomatic CRC and unresectable CRLM have limitations,
and the routine use of surgery in all patients in this group
might not be justified. Therefore, surgery is no longer
routinely considered as an initial therapeutic interven-
tion, and the appropriateness of resection has been ques-
tioned in this setting. Thus, recently resection is hesitantlyoffered as an alternative with ill-defined indications and
mixed results.
Conclusions
The classic, combined, and reverse strategies are associ-
ated with similar outcomes. While some authors argue
that the mortality and morbidity of major liver resection,
combined with bowel resection, are likely to be consider-
able, with some studies showing an increase of more than
threefold, others disagree with this view. Despite experi-
ences reported by some authors, there is no consensus as
yet for the role of the liver-first strategy in improving
long-term survival in patients with CRLM. The benefit
of chemotherapy in neoadjuvant or adjuvant setting for re-
sectable CRLM has not been rigorously validated in clinical
trials. There are several proposed management strategies
for patients with disappearing liver metastases. However,
no strong evidence from randomized controlled trials ex-
ists to support either of these management options.
All these controversies surrounding the management
of CRLM underscore the need for large-scale, multicenter
randomized trials to better define effective therapeutic
strategies for clinically meaningful long-term outcomes. In
the absence of high-quality evidence, disease management
of CRLM needs to be personalized, balancing potential
risks and benefits of treatment (and related uncertainties)
with risk of the disease (Figure 1).
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